Identifies TYK2 mutation as a factor in severe kerion infection, suggesting increased infection risk with TYK2-targeted therapies.
We identified a heterozygous dominant-negative TYK2 mutation (p.Y108°C) in a 74-year-old patient with severe, refractory kerion caused by Trichophyton violaceum. This mutation abolished IL-23/STAT3 signalling, impaired Th17 cell differentiation, and led to absent S100A8 expression and futile neutrophilic inflammation in Tyk2-knockout mice. Our findings establish a non-redundant role for TYK2 in cutaneous defence against dermatophytes and raise caution for potential susceptibility to such infections in patients receiving TYK2-targeted therapies.
No takes yet. Share an insight, caveat, or question.
Xue et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: